Sucampo Pharma (SCMP) Tops Q3 EPS by 2c, Guidance Beats
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/3/2026
- Dow jumps to record closing high after soft US jobs data, Nasdaq down with chip shares
- Goldman's Garrett sees investors dialing back tech exposure into H2
- AI chip winners may face tougher road ahead as hyperscalers catch up: JPM
- Oil gains on short-covering buys ahead of US holiday
- Rivian stock jumps 5% on raised delivery outlook
- Analysis-Excommunications show a Pope Leo unafraid of making firm decisions
- Dow jumps to record closing high after soft US jobs data, Nasdaq down with chip shares
- Canaccord Starts Infleqtion, Inc (INFQ) at Buy
- Jersey Mike's Subs files for IPO on NYSE under ticker JMKE
- AXT-Tongmei signs 3-year wafer supply deal with Coherent
Sucampo Reports Third Quarter 2016 Financial Results
November 9, 2016 6:30 AM ESTResults Driven by 73% Growth in Revenue
GAAP EPS Growth of 12%; Adjusted EPS Growth of 58%
Company Raises 2016 Guidance and Provides Preliminary 2017 Guidance
Announces Settlement with Dr. Reddys Laboratories for AMITIZA
Reports Phase Three Results for AMITIZA in Pediatric Population
Company to Host Conference Call Today at 8:30 a.m. EST
ROCKVILLE, Md., Nov. 09, 2016 (GLOBE NEWSWIRE) -- Sucampo Pharmaceuticals,... More
